University of Colorado Hospital-affiliated UC Health and University of Virginia LVG Venture Fund both featured in a series A round for healthcare analytics platform creator RxRevu.

US-based medical prescription decision-making tool developer RxRevu closed a $15.9m series A round yesterday led by UCHealth, a nonprofit healthcare system which contains academic medical centre University of Colorado Hospital. The deal was backed by University of Virginia’s LVG Venture Fund and Inception Health, a medical innovation partnership between health system Froedtert Health and the Medical College of Wisconsin. Children’s Hospital Colorado also provided funding to RxRevu, as did medical care providers Presbyterian Healthcare Services and UnityPoint Health, venture capital firm Jazz Venture Partners and undisclosed existing investors. Founded in 2013, RxRevu has built a software platform, SwiftRx, and related tools to help inform decisions on which medications to prescribe to patients. SwiftRx achieves this by providing real-time information on factors such as drug prices in combination with personal medical information sourced from the patient’s electronic health record. The software also features behavioural analytics-driven tools to help clinicians manage patient safety and pharmacy risk. and can handle complex sets of data presented in advanced fields of patient management such as pharmacogenomics. RxRevu has worked alongside UCHealth’s Care Innovation Center over the past two years in a co-development partnership. Richard Zane, chief innovation officer at UCHealth, and Toby Cosgrove, executive adviser at academic medical centre Cleveland Clinic, have now the board of directors in conjunction with the round. RxRevu received $3.8m in convertible notes from undisclosed investors across three tranches in 2014 and 2016, before some of the notes were exchanged in a $4.7m equity round in 2017 also backed by unnamed investors, according to regulatory filings.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?